(Z)-5-((2-(cyclohexylamino)pyrimidin-4-yl)methylene)thiazolidine-2,4-dione | 1312663-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (Z)-5-((2-(cyclohexylamino)pyrimidin-4-yl)methylene)thiazolidine-2,4-dione
• 英文别名: (5Z)-5-[[2-(cyclohexylamino)pyrimidin-4-yl]methylidene]-1,3-thiazolidine-2,4-dione
• CAS: 1312663-15-2
• 化学式: C₁₄H₁₆N₄O₂S
• 分子量: 304.373
• InChiKey: LHSTZFPMBGDWSI-FLIBITNWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Aminopyrimidine Kinase Inhibitors
  申请人：Baldino Carmen M.

  公开号：US20110152235A1

  公开（公告）日：2011-06-23

  Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

  揭示了化合物、含有这些化合物的药物组合物，以及这些化合物和组合物作为酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim 1、Pim2、Pim3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径调节剂的用途。还揭示了用于治疗或预防一系列治疗适应症的用途，至少部分原因是由于酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim 1、Pim2、Pim3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径的异常生理活性。
• Aminopyrimidine kinase inhibitors
  申请人：Jasco Pharmaceuticals, LLC

  公开号：US10336743B2

  公开（公告）日：2019-07-02

  Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.

  公开了化合物、含有这些化合物的药物组合物，以及这些化合物和组合物作为CK1、CK1γ1、CK1γ2、CK1γ3、CK2、Pim 1、Pim2、Pim3、TGFβ通路、Wnt通路、JAK/STAT通路、AKT通路和/或mTOR通路调节剂的用途。还公开了用于治疗或预防至少部分由 CK1、CK1γ1、CK1γ2、CK1γ3、CK2、Pim 1、Pim2、Pim3、TGFβ 通路、Wnt 通路、JAK/STAT 通路、AKT 通路和/或 mTOR 通路的异常生理活性引起的一系列治疗适应症的用途。
• AMINOPYRIMIDINE KINASE INHIBITORS
  申请人：Jasco Pharmaceuticals LLC

  公开号：EP2516425A1

  公开（公告）日：2012-10-31
• US8563539B2
  申请人：——

  公开号：US8563539B2

  公开（公告）日：2013-10-22
• US9157077B2
  申请人：——

  公开号：US9157077B2

  公开（公告）日：2015-10-13